Multiple Sclerosis and Kidney Disease 2021 Conferences Investor Hub

BPIQ
Oct 12, 2021
4 min read

Summary

Upcoming biopharma conferences that will release abstracts in October 2021 include the Consortium of Multiple Sclerosis Centers (CMSC) and ASN (American Society of Nephrology) Kidney Week
Kidney Week is hosted from November 4-7, 2021 and is 100% virtual this year
CMSC is hosted from October 25-28, 2021 and will have a virtual component along with an in-person meeting in Orlando, Florida
Read more about the companies presenting at these conferences and their specific embargo policies HERE. [Take your biotech investing to the next level with our research companion, try free today, learn more here!]

Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter

ASN Kidney Week

ASN Kidney Week is the "World's premier nephrology meeting" (https://www.asn-online.org/education/kidneyweek/2019/?dothis=unlock) and in 2019 hosted over 13,000 kidney professionals across the globe in Washington, DC. Kidney Week 2021 was expected to include a virtual and in-person portion (happening in San Diego, California); however, the Education Committee decided to host the 2021 conference fully virtual because of the COVID-19 delta variant. All meeting content will be available on the Kidney Week platform starting on November 4, 2021 until January 7, 2021 and then for a further three years on the ASN eLearning Center. New in 2021 is the fully virtual “Early Programs” portion which will provide on-demand content programs starting October 25 as well as a COVID-19 panel (with Dr. Fauci as the Keynote speaker) with a focus on kidney health. The annual meeting will run from November 4 - 7, 2021 and include “virtual sessions, ePosters, virtual exhibits, networking activities, and much more.” https://www.asn-online.org/education/kidneyweek/2021/meeting-overview.aspx

CMCS

The 2021 CMSC annual meeting is a hybrid meeting including a virtual aspect and onsite aspect in Orlando, Florida. The virtual meeting in 2020 included over 3,000 registrants for educational sessions, over 1200 registrants in the exhibits and 18 sessions. https://cmscscholar.org/2020-virtual-meeting/. For the 2021 meeting, streamed sessions will be recorded and available on-demand for six months. The titles of abstracts are currently available (https://cmscscholar.org/2021-accepted-abstracts-titles-and-authors/) and full abstracts will be available starting October 25, 2021. Posters at CMSC include case reports, disease-modifying therapy, epidemiology, family and caregivers, and much more.

Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. As experienced biopharma investors understand, the value of a biopharma company is based in large part on the value of its clinical assets. This value takes into account the likelihood of success of the clinical assets of the underlying company in successfully completing clinical trials. An update to a clinical trial that shows some positive results in safety and especially efficacy, can increase the chance of success for that trial, which increases the value of the asset and the underlying company. The converse is true as well, for disappointing results.

Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.

With respect to CMSC, Kidney Week, and biomedical conferences in general, a big challenge for investors is to identify in advance, companies that are reporting significant clinical trial updates at the conference. Many presentations provide less significant information with respect to company valuation (e.g. preclinical results or clinical trial design). At BiopharmIQ (BPIQ.com; "BPIQ") we oversee a database of information about clinical assets and their upcoming clinical trial and other catalyst events for virtually every biopharma company with a market cap of between $100M and $5B, which for convenience in this article, we will refer to as smid-cap biopharma companies. Currently, our database has over 550 smid-cap biopharma companies. Our goal at BPIQ is to provide information and education on smid-CAP biopharma companies to level the playing field for all investors, whether retail, professional or institutional.

To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting at these upcoming conferences and if new data will be provided. Table 1 lists those companies in our BPIQ database that are presenting at ASN Kidney Week and Table 2 lists those companies in our BPIQ database that are presenting at CMSC (both provided at the end of this article). These tables provide the drug candidate name, indication, and phase of data to be presented. To see more information about these trials including data expected at CMSC and Kidney week visit our full forum article HERE after signing up. Learn more here.

The question for biopharma investors now with respect to the actual CMSC and Kidney Week meetings is which stocks or groups of stocks are likely to move upon the release of the abstracts, posters, or associated investor meeting. We plan to update information about the presentations on BPIQ.com as they become available. In the meantime, the information provided in this article provides an interesting snapshot into the smid-cap biopharma companies that are developing some of the leading medicines for multiple sclerosis and kidney diseases. For investors, these companies represent an exciting opportunity for further diligence and possible investment.

Table 1. BPIQ.com smid-cap companies presenting at Kidney Week 2021

Table 2. BPIQ.com smid-cap companies presenting at CMSC 2021

If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.

Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!

Try BPIQ Free Today

See what our members are saying about us:

Mike from United States

“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”

Carl from United States

“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”

Essey from Canada

“Love what you’re doing, this website is awesome.”

James from United States

Great site and I see it’s a family run business, great job.”